Pharmaceuticals, Biotechnology and Life Sciences
ZW25 Plus Chemotherapy Shows Durable Activity in Patients with Heavily Pretreated Gastroesophageal Adenocarcinoma Data Continue to Support Ongoing Phase 2…
VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the appointment of Kathryn…
Zymerowks’ data for HER2-targeted biospecific antibody ZW25, which will be presented at ESMO, support the Initiation of a Registration-Enabling Phase 2 Trial of the ZW25 in second-line HER2-expressing biliary tract cancers.
VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics (the “Company”), announced today the pricing of…